Neoadjuvant chemotherapy in cervical cancer in pregnancy

• Cervical cancer is the most common gynecological cancer encountered in pregnancy.
• A multidisciplinary approach is vital in the management of this condition.
• Neoadjuvant chemotherapy (NACT) helps delay delivery until fetal maturity is achieved.
• In selected cases, NACT may allow fertility preservation.
• Cisplatin is the most widely studied chemotherapeutic agent in pregnancy.

Cervical cancer is the most common gynecological cancer encountered in pregnancy. The standard treatment of early cervical cancer is usually surgical removal of the cervix (in selected cases) or, more commonly, the uterus. However, when cervical cancer develops during pregnancy, definitive surgical treatment often needs to be postponed until the fetus reaches maturity. Neoadjuvant chemotherapy (NACT) is an innovative approach in the management of these patients. It helps in controlling the disease and delaying delivery. The paper presents a literature review of the history of NACT, as well as practice points and agenda for further research.